Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma

Kelly E. Craven, Jesse Gore, Murray Korc

Research output: Contribution to journalShort survey

24 Scopus citations

Abstract

The importance of angiogenesis in pancreatic ductal adenocarcinoma (PDAC) and its therapeutic potential have been explored in both pre-clinical and clinical studies. Human PDACs overexpress a number of angiogenic factors and their cognate high-affinity receptors, and anti-angiogenic agents reduce tumor volume, metastasis, and microvessel density (MVD), and improve survival in subcutaneous and orthotopic pre-clinical models. Nonetheless, clinical trials using anti-angiogenic therapy have been overwhelmingly unsuccessful. This review will focus on these pre-clinical and clinical studies, the potential reasons for failure in the clinical setting, and ways these shortcomings could be addressed in future investigations of angiogenic mechanisms in PDAC.

Original languageEnglish (US)
Pages (from-to)201-210
Number of pages10
JournalCancer Letters
Volume381
Issue number1
DOIs
StatePublished - Oct 10 2016

Keywords

  • Angiogenesis
  • Pancreatic cancer
  • Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma'. Together they form a unique fingerprint.

  • Cite this